Evotec

(IN BRIEF) Evotec SE’s subsidiary Just – Evotec Biologics has been selected by the Biomedical Advanced Research and Development Authority BioMaP Consortium to support a multi-year initiative aimed at improving manufacturing processes for antibody-based treatments targeting Ebola and Sudan virus. … Read the full press release →

(IN BRIEF) Evotec SE has created a new Executive Vice President role that combines Global Communications and Investor Relations as part of a broader effort to strengthen strategic clarity and stakeholder engagement. Dr. Sarah Fakih has been appointed to lead … Read the full press release →

(IN BRIEF) Evotec SE announced that Bayer has initiated a Phase 2 clinical study for BAY 3401016, a Semaphorin-3A-targeting monoclonal antibody being developed as a potential therapeutic option for patients with Alport syndrome. As part of the companies’ kidney disease … Read the full press release →

(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research … Read the full press release →

(IN BRIEF) Evotec SE has announced that Esperion Therapeutics has nominated an oral preclinical development candidate for primary sclerosing cholangitis (PSC), marking a major milestone in their collaboration. The PDC, developed through Evotec’s integrated small molecule discovery platform and Esperion’s … Read the full press release →

(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release →

(IN BRIEF) Evotec, Yonsei University, and Zymedi have been awarded a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF). The project … Read the full press release →

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases. The projects, from Boston University, Harvard University in collaboration with Mass General Brigham, … Read the full press release →

(IN BRIEF) Evotec SE announced that Dr. Craig Johnstone, the company’s Chief Operating Officer, will step down on 31 December 2024. Dr. Johnstone joined Evotec in 2012 and held various leadership roles, including Global Head of Integrated Drug Discovery and … Read the full press release →

(IN BRIEF) Evotec SE has sold its chemical API-focused manufacturing site, Evotec DS GmbH, to Monacum Partners as part of its “Priority Reset” strategy to focus on core growth areas. The Halle/Westphalia-based facility, now renamed DAPIN GmbH, will continue its … Read the full press release →

(IN BRIEF) Evotec SE has made significant progress in its strategic partnership with Bristol Myers Squibb, focused on developing a molecular glue-based therapy pipeline. This success has led to $75 million in milestone payments to Evotec. The partnership, which began … Read the full press release →

(IN BRIEF) Just – Evotec Biologics and Sandoz have expanded their strategic partnership to advance the development and commercial manufacturing of biosimilars. This enhanced collaboration includes additional biosimilars in Sandoz’s pipeline and ensures long-term supply through Just – Evotec Biologics’ … Read the full press release →

(IN BRIEF) Evotec SE announces a partnership with Inserm, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic markers in obesity and metabolic diseases. The collaboration, centered around the ABOS/DIABOMICS study led by Lille University Hospital, … Read the full press release →

(IN BRIEF) Bayer and Evotec have updated their strategic collaboration to focus on developing precision treatments for cardiovascular diseases (CVDs). Leveraging Evotec’s expertise in disease modelling using human induced pluripotent stem cells (iPSCs), the collaboration aims to identify and validate … Read the full press release →

(IN BRIEF) Evotec Biologics, the biologics arm of Evotec SE, has introduced its proprietary J.CHO™ High Expression System for antibody expression. J.CHO™ optimizes biotherapeutic production processes by providing higher productivity and quality for complex antibody formats. Engineered from Chinese hamster … Read the full press release →

(IN BRIEF) Evotec SE announces the appointment of Aurélie Dalbiez as their new Chief People Officer (CPO), effective June 15, 2024. Joining the Management Board, Aurélie brings over 25 years of international Human Resources leadership experience, previously serving as the … Read the full press release →

(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release →

(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release →

(IN BRIEF) Evotec and Claris Ventures have formed a strategic partnership to accelerate the progress of biotech ventures in Claris’s portfolio into clinical trials. This collaboration allows Claris’s portfolio companies, focused on biotech ventures nearing clinical trials, streamlined access to … Read the full press release →